(Q37617521)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

review article

1 reference

title

Biological marker candidates of Alzheimer's disease in blood, plasma, and serum (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Philine Schneider

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Katharina Buerger

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

14 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

CNS Neuroscience & Therapeutics

10 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

358-374

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

10 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Altered amyloid protein processing in platelets of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Platelet APP isoform ratios correlate with declining cognition in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2009.00104.X

Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease.

21 January 2018

1 reference

12 December 2020

Mitochondrial involvement in Alzheimer's disease

1 reference

12 December 2020

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

12 December 2020

Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia.

1 reference

12 December 2020

Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease

1 reference

12 December 2020

Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease.

1 reference

12 December 2020

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

1 reference

12 December 2020

Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

1 reference

12 December 2020

Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients

1 reference

12 December 2020

Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations.

1 reference

12 December 2020

Genetic testing for Alzheimer's disease.

1 reference

12 December 2020

Inflammation and Alzheimer's disease

1 reference

12 December 2020

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

12 December 2020

Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project

1 reference

12 December 2020

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

1 reference

12 December 2020

Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity

1 reference

12 December 2020

Statins and the risk of dementia

1 reference

12 December 2020

Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses

1 reference

12 December 2020

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

1 reference

12 December 2020

Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment

1 reference

12 December 2020

Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.

1 reference

12 December 2020

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

1 reference

12 December 2020

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.

1 reference

12 December 2020

Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments

1 reference

12 December 2020

Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.

1 reference

12 December 2020

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study

1 reference

12 December 2020

Autoantibodies to amyloid-beta and Alzheimer's disease.

1 reference

12 December 2020

Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide

1 reference

12 December 2020

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

1 reference

12 December 2020

24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia

1 reference

12 December 2020

Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease.

1 reference

12 December 2020

Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain

1 reference

12 December 2020

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

1 reference

12 December 2020

Serum lipoprotein levels, statin use, and cognitive function in older women

1 reference

12 December 2020

Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls

1 reference

12 December 2020

Alzheimer's disease and oxygen radicals: new insights

1 reference

12 December 2020

Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid

1 reference

12 December 2020

Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease

1 reference

12 December 2020

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

1 reference

12 December 2020

The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

1 reference

12 December 2020

Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease

1 reference

12 December 2020

Serum creatinine levels correlate with plasma amyloid Beta protein

1 reference

12 December 2020

Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications

1 reference

12 December 2020

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

1 reference

12 December 2020

Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death

1 reference

12 December 2020

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

12 December 2020

Inflammation and therapeutic vaccination in CNS diseases

1 reference

12 December 2020

Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.

1 reference

12 December 2020

Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers.

1 reference

12 December 2020

Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease.

1 reference

12 December 2020

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

12 December 2020

Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians

1 reference

12 December 2020

Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study.

1 reference

12 December 2020

Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease

1 reference

12 December 2020

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

1 reference

12 December 2020

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

1 reference

12 December 2020

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

1 reference

12 December 2020

APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis

1 reference

12 December 2020

CSF markers for incipient Alzheimer's disease

1 reference

12 December 2020

Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk

1 reference

12 December 2020

Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics

1 reference

12 December 2020

Inflammatory proteins in plasma and the risk of dementia: the rotterdam study

1 reference

12 December 2020

Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients

1 reference

12 December 2020

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele

1 reference

12 December 2020

Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain

1 reference

12 December 2020

Biomarkers of Alzheimer disease in plasma

1 reference

12 December 2020

Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients.

1 reference

12 December 2020

Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease

1 reference

12 December 2020

Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide.

1 reference

12 December 2020

Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment

1 reference

12 December 2020

Selective Reductions in Plasma A 1-42 in Healthy Elderly Subjects During Longitudinal Follow-Up: A Preliminary Report

1 reference

12 December 2020

Vitamin C and Vitamin E for Alzheimer's Disease

1 reference

12 December 2020

Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease

1 reference

12 December 2020

Lipid metabolism in cognitive decline and dementia

1 reference

12 December 2020

Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease

1 reference

12 December 2020

The involvement of lipid rafts in Alzheimer's disease

1 reference

12 December 2020

Microvascular injury and blood-brain barrier leakage in Alzheimer's disease

1 reference

12 December 2020

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

1 reference

12 December 2020

Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.

1 reference

12 December 2020

Proteome-based plasma biomarkers for Alzheimer's disease

1 reference

12 December 2020

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

1 reference

12 December 2020

Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association

1 reference

12 December 2020

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

1 reference

12 December 2020

Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease.

1 reference

12 December 2020

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

1 reference

12 December 2020

Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease

1 reference

12 December 2020

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease

1 reference

12 December 2020

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

1 reference

12 December 2020

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

1 reference

12 December 2020

Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease

1 reference

12 December 2020

Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.

1 reference

12 December 2020

Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers.

1 reference

12 December 2020

Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio.

1 reference

12 December 2020

Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease

1 reference

12 December 2020

Statins: mechanisms of neuroprotection

1 reference

12 December 2020

Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).

1 reference

12 December 2020

The amyloid precursor protein of Alzheimer's disease is released by human platelets.

1 reference

12 December 2020

Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia

1 reference

12 December 2020

Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease.

1 reference

12 December 2020

Expression of apolipoprotein E during nerve degeneration and regeneration

1 reference

12 December 2020

Lipid peroxidation and free radical scavengers in Alzheimer's disease

1 reference

12 December 2020

Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease

1 reference

12 December 2020

Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease

1 reference

12 December 2020

Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response

1 reference

12 December 2020

Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

1 reference

12 December 2020

Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease

1 reference

12 December 2020

Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease.

1 reference

12 December 2020

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

1 reference

12 December 2020

Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques

1 reference

12 December 2020

Serum cytokine levels in patients with Alzheimer's disease

1 reference

12 December 2020

Clinical and pathological correlates of apolipoprotein E ?4 in Alzheimer's disease

1 reference

12 December 2020

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

1 reference

12 December 2020

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

1 reference

12 December 2020

Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease.

1 reference

12 December 2020

Brain infarction and the clinical expression of Alzheimer disease. The Nun Study

1 reference

12 December 2020

Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease.

1 reference

12 December 2020

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

12 December 2020

Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele.

1 reference

12 December 2020

Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease.

1 reference

12 December 2020

Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease.

1 reference

12 December 2020

Circulating cytokines in Alzheimer's disease.

1 reference

12 December 2020

Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

12 December 2020

Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease

1 reference

12 December 2020

Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group

1 reference

12 December 2020

Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease.

1 reference

12 December 2020

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

1 reference

12 December 2020

Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study

1 reference

12 December 2020

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

12 December 2020

Alzheimer disease-related abnormalities of amyloid beta precursor protein isoforms in the platelet: the brain's delegate in the periphery?

1 reference

12 December 2020

Differential Level of Platelet Amyloid beta Precursor Protein Isoforms: An Early Marker for Alzheimer Disease

1 reference

12 December 2020

Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor rece

1 reference

12 December 2020

Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT.

1 reference

12 December 2020

Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo.

1 reference

12 December 2020

10.1111/J.1755-5949.2009.00104.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19840034%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference